Yanhui Li

Title: Yanhui Li: Innovator in Cancer Treatment

Introduction

Yanhui Li is a notable inventor based in Shijiazhuang, China. He has made significant contributions to the field of oncology, particularly in the treatment of peripheral T-cell lymphoma (PTCL). His innovative approach combines various therapeutic agents to enhance treatment efficacy and patient safety.

Latest Patents

Yanhui Li holds a patent for the "Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone." This patent outlines a method for treating PTCL, specifically targeting treatment-naïve patients. The method involves administering a therapeutically effective amount of the aforementioned drugs, which has been shown to be safe and tolerable with minimal toxicity and side effects. The combined administration of these drugs aims to achieve a higher total objective remission rate in patients suffering from PTCL.

Career Highlights

Yanhui Li is associated with Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., where he continues to work on innovative solutions for cancer treatment. His research focuses on improving therapeutic outcomes for patients with PTCL through the development of effective drug combinations.

Collaborations

Yanhui Li collaborates with esteemed colleagues, including Chunlei Li and Xuefang Xia, to advance research in cancer therapies. Their combined expertise contributes to the development of innovative treatment options for patients.

Conclusion

Yanhui Li's contributions to cancer treatment through his patent and collaborative efforts highlight his commitment to improving patient outcomes in oncology. His work exemplifies the importance of innovation in the medical field.